Cargando…
Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases
Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504155/ https://www.ncbi.nlm.nih.gov/pubmed/36145298 http://dx.doi.org/10.3390/ph15091077 |
_version_ | 1784796145007984640 |
---|---|
author | Ashraf, Hajra Solla, Paolo Sechi, Leonardo Atonio |
author_facet | Ashraf, Hajra Solla, Paolo Sechi, Leonardo Atonio |
author_sort | Ashraf, Hajra |
collection | PubMed |
description | Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous symptoms. Multiple sclerosis (MS) is the most prevalent autoimmune neurological disease while NMO spectrum disorder (NMOSD) is less common. Furthermore, evidence supports the presence of autoimmune mechanisms contributing to the pathogenesis of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by the progressive death of motor neurons. Additionally, autoimmunity is believed to be involved in the basis of Alzheimer’s and Parkinson’s diseases. In recent years, the prevalence of autoimmune-based neurological disorders has been elevated and current findings strongly suggest the role of pharmacotherapies in controlling the progression of autoimmune diseases. Therefore, this review focused on the current advancement of immunomodulatory drugs as novel approaches in the management of autoimmune neurological diseases and their future outlook. |
format | Online Article Text |
id | pubmed-9504155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95041552022-09-24 Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases Ashraf, Hajra Solla, Paolo Sechi, Leonardo Atonio Pharmaceuticals (Basel) Review Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous symptoms. Multiple sclerosis (MS) is the most prevalent autoimmune neurological disease while NMO spectrum disorder (NMOSD) is less common. Furthermore, evidence supports the presence of autoimmune mechanisms contributing to the pathogenesis of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disorder characterized by the progressive death of motor neurons. Additionally, autoimmunity is believed to be involved in the basis of Alzheimer’s and Parkinson’s diseases. In recent years, the prevalence of autoimmune-based neurological disorders has been elevated and current findings strongly suggest the role of pharmacotherapies in controlling the progression of autoimmune diseases. Therefore, this review focused on the current advancement of immunomodulatory drugs as novel approaches in the management of autoimmune neurological diseases and their future outlook. MDPI 2022-08-29 /pmc/articles/PMC9504155/ /pubmed/36145298 http://dx.doi.org/10.3390/ph15091077 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ashraf, Hajra Solla, Paolo Sechi, Leonardo Atonio Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title | Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title_full | Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title_fullStr | Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title_full_unstemmed | Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title_short | Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases |
title_sort | current advancement of immunomodulatory drugs as potential pharmacotherapies for autoimmunity based neurological diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504155/ https://www.ncbi.nlm.nih.gov/pubmed/36145298 http://dx.doi.org/10.3390/ph15091077 |
work_keys_str_mv | AT ashrafhajra currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases AT sollapaolo currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases AT sechileonardoatonio currentadvancementofimmunomodulatorydrugsaspotentialpharmacotherapiesforautoimmunitybasedneurologicaldiseases |